secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001558370-24-011459
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio reports Q2 net loss $16M; advances upliFT-D trial, out-licenses programs to GEMMABio
--------------------------------------------------------------------------------

- Enrolled first FTD-GRN patient in Cohort 2 of upliFT-D trial; FDA agreed to expand trial to FTD-C9orf72 patients.
- Out-licensed pediatric LSD programs to GEMMA Biotherapeutics; initial payments $10M, potential milestones up to $114M plus royalties.
- Cash $91.8M as of June 30, 2024; cash runway extended to end of Q2 2026.
- Net loss $16.0M ($0.26/share) vs $23.9M ($0.44/share) in Q2 2023; R&D and G&A expenses decreased.
- Plan to present updated safety and biomarker data from Cohort 1 at ISFTD2024 in September.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000155837024011459/0001558370-24-011459-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000155837024011459/pasg-20240808x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-011459

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer